Patients without the risk allele, especially those with previous adverse reactions to thiopurines or methotrexate, or those at high risk for opportunistic infections, may avoid the added risks of combination therapy and be well-managed with ADA or IFX monotherapy. Here, ADA is linked to Opportunistic infection.